Agarwal Arjun 4

What Happened
Arjun Agarwal, Senior Vice President, Finance at Oruka Therapeutics (ORKA), was granted two awards on January 23, 2026: 17,500 shares (awarded at $0.00) and a 70,000-share derivative award (also recorded at $0.00). These were grants/awards (not open-market purchases or sales), so Agarwal did not pay cash for the awards at grant.

Key Details

• Transaction date: 2026-01-23. Acquisition type: Awards/Grants (code A). Reported acquisition price: $0.00 for both awards. Total reported cash paid: $0.
• Award specifics:
  • 17,500 shares (direct award) — footnote F1: vests 1/16 of the shares on each March 14, June 14, September 14 and December 14 (or the preceding trading day if not a trading day).
  • 70,000-share derivative award (likely stock option or similar) — footnote F3: vests 1/48 of the underlying shares monthly beginning January 1, 2026.
• Additional note: footnote F2 states the reporting includes 1,758 shares acquired under Oruka’s employee stock purchase plan on December 8, 2025.
• Shares owned after the reported transactions: not specified in the filing.
• Filing timeliness: filing date equals transaction date (filed 2026-01-23 for transactions on 2026-01-23), so no late filing indicated.

Context
These are time‑based compensation awards (one direct share award and one derivative award with monthly vesting). Such grants are common for executives and are not the same signal as an open-market purchase or sale. Vesting schedules mean the shares/options will become usable over the next few years rather than immediately.